medcelerator · clinician one-pager
New Pill for Ovarian Cancer That No Longer Responds to Chemo
Lifyorli (relacorilant) — oral GR antagonist with nab-paclitaxel for platinum-resistant ovarian cancer
FDA Approved · United States · September 11, 2026
Condition: Ovarian Cancer
Who this is for
This is for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior systemic regimens (including prior bevacizumab) who may be candidates for labelled US Lifyorli plus nab-paclitaxel. It explains the full FDA label, the ROSELLA progression-free and overall survival numbers, neutropenia and adrenal-insufficiency watchpoints, how the peri-infusion capsule schedule works with weekly nab-paclitaxel, and how to talk with a gynecologic oncology clinician — without treating a Canadian trial site, an EMA MAA under review, or a DIY import as the care plan. Authorized is not funded.
Next clinical step
The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.
Ways to access this treatment
United States · Prescription
US prescription (FDA-labelled)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220641Orig1s000lbl.pdf
General resources for further research
ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/
AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/lifyorli-relacorilant